{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-357380","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2021-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.244284+00:00","generated_at":"2026-06-28T01:03:48.880344+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lilly raises 2021 revenue guidance to $28.0B-$28.3B; 2022 EPS seen at $8.00-$8.15","bullets":["2021 revenue guidance raised to $28.0B-$28.3B (from $27.2B-$27.6B); non-GAAP EPS raised to $8.15-$8.20.","2022 revenue guidance $27.8B-$28.3B; reported EPS $8.00-$8.15; non-GAAP EPS $8.50-$8.65.","Initiated rolling FDA submission for pirtobrutinib in MCL; completion in 2022, regulatory action early 2023.","Plans new phase 3 studies for tirzepatide in obesity outcomes, sleep apnea, and kidney disease; donanemab biomarker data disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-357380","json":"https://secwatch.observer/filing/0001193125-21-357380.json","markdown":"https://secwatch.observer/filing/0001193125-21-357380.md","text":"https://secwatch.observer/filing/0001193125-21-357380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000119312521357380/0001193125-21-357380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000119312521357380/d212746d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:03:48.880344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}